Pfizer (NYSE:PFE) Trading Up 0.4% – What’s Next?

Pfizer Inc. (NYSE:PFE) shares were up 0.4% during mid-day trading on Friday . The stock traded as high as $25.74 and last traded at $25.70. Approximately 6,448,286 shares traded hands during trading, a decline of 84% from the average daily volume of 39,356,457 shares. The stock had previously closed at $25.60.

Analyst Ratings Changes

A number of brokerages have recently commented on PFE. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

The company has a market cap of $145.23 billion, a P/E ratio of 18.17, a P/E/G ratio of 0.64 and a beta of 0.61. The stock has a 50-day simple moving average of $26.26 and a 200 day simple moving average of $27.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pfizer

Large investors have recently modified their holdings of the stock. Swedbank AB lifted its stake in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the period. United Bank boosted its stake in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 1,277 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of Pfizer during the 3rd quarter worth approximately $860,000. GSA Capital Partners LLP raised its stake in shares of Pfizer by 87.6% during the third quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after buying an additional 15,310 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Pfizer by 52.6% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 31,723 shares of the biopharmaceutical company’s stock valued at $919,000 after buying an additional 10,938 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.